Spruce Biosciences, Inc. (NasdaqCM: SPRB)
Health Care · Biotechnology · US
$42.87
-2.68% today · -72.3% 1Y
Spruce Biosciences, Inc. (NasdaqCM: SPRB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $126.60M and employs 22 people.
Over the last twelve months the share price has lost 72.3%, trading between 40.33 and 199.20.
Tweenvest scores Spruce Biosciences, Inc. across four factors: quality 35/100, value 88/100. Its strongest factor is value.
SPRB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $126.60M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -36.05
- Dividend yield
- —
- Beta (5Y)
- 3.30
- 52-week high
- $199.20
- 52-week low
- $40.33
- Avg volume (3M)
- —
- Shares outstanding
- 2.87M
- Employees
- 22
- Next earnings
- —
About Spruce Biosciences, Inc.
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.
- ISIN
- US85209E2081
- Founded
- 2014
- Listed since
- Oct 9, 2020
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Saniona AB (publ)OM: SANION | $132.11M | Skr9.57 | -0.26% |
| Orthocell LimitedASX: OCC | $131.16M | AU$0.69 | -9.21% |
| Tenaya Therapeutics, Inc.NasdaqCM: TNYA | $130.12M | $0.57 | -2.55% |
| NKGen Biotech Korea Co., Ltd.KOSDAQ: A182400 | $128.86M | ₩— | — |
| Bio Solution Co.,Ltd.KOSDAQ: A086820 | $126.49M | ₩6,590.00 | -1.64% |
| Pharma Foods International Co., Ltd.TSE: 2929 | $126.01M | ¥687.00 | +1.33% |
| Aroa Biosurgery LimitedASX: ARX | $125.52M | AU$0.52 | +6.12% |
| Bioventix PLCAIM: BVXP | $124.94M | £17.75 | -1.93% |
Figures last refreshed Oct 11, 2026.